Targeting Astrocytes for Stroke Therapy

Neurotherapeutics

Volumn 7, Issue 4, 2010, Pages 439-451

  Zhao, Yanxin ^a   Rempe, David A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Astrocyte; Glutamate; Inflammation; Ischemia; Stroke; Translation

Indexed keywords

ADENOSINE; ADRENOMEDULLIN; ARUNDIC ACID; CARBENOXOLONE; CEFTRIAXONE; CONNEXIN 43; CYTOKINE; ENZYME INHIBITOR; ERYTHROPOIETIN; GLUTAMIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MATRIX METALLOPROTEINASE; NEUROTROPHIN; PLACEBO; PROLYL HYDROXYLASE INHIBITOR; PROTEIN S100B; THROMBOSPONDIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; ASTROCYTE; BRAIN EDEMA; BRAIN HYPOXIA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL FUNCTION; CELL SURVIVAL; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONVALESCENCE; DISABILITY; DOSE RESPONSE; DRUG SCREENING; DRUG TARGETING; HOMEOSTASIS; HUMAN; INFLAMMATION; MIDDLE CEREBRAL ARTERY OCCLUSION; MOLECULAR MECHANICS; MORTALITY; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROKE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ASTROCYTES; ENCEPHALITIS; GLUTAMIC ACID; HUMANS; NERVE GROWTH FACTORS; S100 PROTEINS; STROKE;

EID: 77957076579     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.07.004     Document Type: Article

References (153)

1. Guo S., Lo E.H. Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke 2009, 40(3 Suppl):S4-S7.
2. Ransom B., Behar T., Nedergaard M. New roles for astrocytes (stars at last). Trends Neurosci 2003, 26:520-522.
3. Iadecola C., Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007, 10:1369-1376.
4. Chen Y., Swanson R.A. Astrocytes and brain injury. J Cereb Blood Flow Metab 2003, 23:137-149.
5. Kimelberg H.K. Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia 2005, 50:389-397.
6. Anderson C.M., Nedergaard M. Astrocyte-mediated control of cerebral microcirculation. Trends Neurosci 2003, 26:340-344. author reply 344-345.
7. Trendelenburg G., Dirnagl U. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia 2005, 50:307-320.
8. Chesler M. Failure and function of intracellular pH regulation in acute hypoxic-ischemic injury of astrocytes. Glia 2005, 50:398-406.
9. Dienel G.A., Hertz L. Astrocytic contributions to bioenergetics of cerebral ischemia. Glia 2005, 50:362-388.
10. Nedergaard M., Dirnagl U. Role of glial cells in cerebral ischemia. Glia 2005, 50:281-286.
11. Giffard R.G., Swanson R.A. Ischemia-induced programmed cell death in astrocytes. Glia 2005, 50:299-306.
12. Rossi D.J., Brady J.D., Mohr C. Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 2007, 10:1377-1386.
13. Asano T., Mori T., Shimoda T., et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord 2005, 4:127-142.
14. Sofroniew M.V. Reactive astrocytes in neural repair and protection. Neuroscientist 2005, 11:400-407.
15. Eroglu C. The role of astrocyte-secreted matricellular proteins in central nervous system development and function. J Cell Commun Signal 2009, 3:167-176.
16. Panickar K.S., Norenberg M.D. Astrocytes in cerebral ischemic injury: morphological and general considerations. Glia 2005, 50:287-298.
17. Almeida A., Delgado-Esteban M., Bolaños J.P., Medina J.M. Oxygen and glucose deprivation induces mitochondrial dysfunction and oxidative stress in neurones but not in astrocytes in primary culture. J Neurochem 2002, 81:207-217.
18. Vangeison G., Carr D., Federoff H.J., Rempe D.A. The good, the bad, and the cell type-specific roles of hypoxia inducible factor-1α in neurons and astrocytes. J Neurosci 2008, 28:1988-1993.
19. Swanson R.A., Farrell K., Stein B.A. Astrocyte energetics, function, and death under conditions of incomplete ischemia: a mechanism of glial death in the penumbra. Glia 1997, 21:142-153.
20. Giffard R.G., Monyer H., Choi D.W. Selective vulnerability of cultured cortical glia to injury by extracellular acidosis. Brain Res 1990, 530:138-141.
21. Giffard R.G., Papadopoulos M.C., van Hooft J.A., Xu L., Giuffrida R., Monyer H. The electrogenic sodium bicarbonate cotransporter: developmental expression in rat brain and possible role in acid vulnerability. J Neurosci 2000, 20:1001-1008.
22. Liu D., Smith C.L., Barone F.C., et al. Astrocytic demise precedes delayed neuronal death in focal ischemic rat brain. Brain Res Mol Brain Res 1999, 68:29-41.
23. Garcia J.H., Yoshida Y., Chen H., et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Pathol 1993, 142:623-635.
24. Lukaszevicz A.C., Sampaïo N., Guégan C., et al. High sensitivity of protoplasmic cortical astroglia to focal ischemia. J Cereb Blood Flow Metab 2002, 22:289-298.
25. Gürer G., Gursoy-Ozdemir Y., Erdemli E., Can A., Dalkara T. Astrocytes are more resistant to focal cerebral ischemia than neurons and die by a delayed necrosis. Brain Pathol 2009, 19:630-641.
26. Barrett K.M., Ding Y.H., Wagner D.P., Kallmes D.F., Johnston K.C. Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy. Stroke 2009, 40:2422-2427. ASAP Investigators.
27. Du C., Hu R., Csernansky C.A., Hsu C.Y., Choi D.W. Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis?. J Cereb Blood Flow Metab 1996, 16:195-201.
28. Zhao B.Q., Wang S., Kim H.Y., et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006, 12:441-445.
29. Baranova O., Miranda L.F., Pichiule P., Dragatsis I., Johnson R.S., Chavez J.C. Neuron-specific inactivation of the hypoxia inducible factor 1 α increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 2007, 27:6320-6332.
30. Smith J.M., Bradley D.P., James M.F., Huang C.L. Physiological studies of cortical spreading depression. Biol Rev Camb Philos Soc 2006, 81:457-481.
31. Shin H.K., Dunn A.K., Jones P.B., Boas D.A., Moskowitz M.A., Ayata C. Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. J Cereb Blood Flow Metab 2006, 26:1018-1030.
32. Mies G., Iijima T., Hossmann K.A. Correlation between peri-infarct DC shifts and ischaemic neuronal damage in rat. Neuroreport 1993, 4:709-711.
33. Iadecola C., Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001, 14:89-94.
34. Iadecola C., Niwa K., Nogawa S., et al. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 2001, 98:1294-1299.
35. Iadecola C., Zhang F., Casey R., Nagayama M., Ross M.E. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997, 17:9157-9164.
36. Endoh M., Maiese K., Wagner J. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 1994, 651:92-100.
37. Iadecola C., Zhang F., Xu S., Casey R., Ross M.E. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995, 15:378-384.
38. Semenza G.L. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009, 24:97-106.
39. Chavez J.C., Baranova O., Lin J., Pichiule P. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 2006, 26:9471-9481.
40. Jelkmann W., Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004, 83:673-686.
41. Zhang Z.G., Zhang L., Jiang Q., et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000, 106:829-838.
42. Harvey B.K., Chang C.F., Chiang Y.H., et al. HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp Neurol 2003, 183:47-55.
43. Hermann D.M., Kilic E., Kügler S., Isenmann S., Bahr M. Adenovirus-mediated GDNF and CNTF pretreatment protects against striatal injury following transient middle cerebral artery occlusion in mice. Neurobiol Dis 2001, 8:655-666.
44. Kitagawa H., Sasaki C., Sakai K., et al. Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1999, 19:1336-1344.
45. Vahedi K., Hofmeijer J., Juettler E., et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007, 6:215-222. DECIMAL, DESTINY, and HAMLET investigators.
46. Papadopoulos M.C., Verkman A.S. Potential utility of aquaporin modulators for therapy of brain disorders. Prog Brain Res 2008, 170:589-601.
47. Zador Z., Stiver S., Wang V., Manley G.T. Role of aquaporin-4 in cerebral edema and stroke. Handb Exp Pharmacol 2009, (190):159-170.
48. Nielsen S., Nagelhus E.A., Amiry-Moghaddam M., Bourque C., Agre P., Ottersen O.P. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997, 17:171-180.
49. Manley G.T., Fujimura M., Ma T., et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000, 6:159-163.
50. Benfenati V., Nicchia G.P., Svelto M., Rapisarda C., Frigeri A., Ferroni S. Functional down-regulation of volume-regulated anion channels in AQP4 knockdown cultured rat cortical astrocytes. J Neurochem 2007, 100:87-104.
51. Feustel P.J., Jin Y., Kimelberg H.K. Volume-regulated anion channels are the predominant contributors to release of excitatory amino acids in the ischemic cortical penumbra. Stroke 2004, 35:1164-1168.
52. Zhang Y., Jin Y., Behr M.J., Feustel P.J., Morrison J.P., Kimelberg H.K. Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia. Exp Neurol 2005, 196:41-46.
53. Zhang Y., Milatovic D., Aschner M., Feustel P.J., Kimelberg H.K. Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Exp Neurol 2007, 204:819-827.
54. Lakhan S.E., Kirchgessner A., Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009, 7:97.
55. Wang Q., Tang X.N., Yenari M.A. The inflammatory response in stroke. J Neuroimmunol 2007, 184:53-68.
56. Bezzi P., Domercq M., Brambilla L., et al. CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001, 4:702-710.
57. Anderson C.M., Swanson R.A. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 2000, 32:1-14.
58. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
59. Boycott H.E., Dallas M., Boyle J.P., Pearson H.A., Peers C. Hypoxia suppresses astrocyte glutamate transport independently of amyloid formation. Biochem Biophys Res Commun 2007, 364:100-104.
60. Dallas M., Boycott H.E., Atkinson L., et al. Hypoxia suppresses glutamate transport in astrocytes. J Neurosci 2007, 27:3946-3955.
61. Taylor C.T., Cummins E.P. The role of NF-κB in hypoxia-induced gene expression. Ann N Y Acad Sci 2009, 1177:178-184.
62. Taylor C.T. Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation. J Physiol 2008, 586:4055-4059.
63. Boycott H.E., Wilkinson J.A., Boyle J.P., Pearson H.A., Peers C. Differential involvement of TNFα in hypoxic suppression of astrocyte glutamate transporters. Glia 2008, 56:998-1004.
64. Rothstein J.D., Patel S., Regan M.R., et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
65. Chu K., Lee S.T., Sinn D.I., et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 2007, 38:177-182.
66. Lee S.G., Su Z.Z., Emdad L., et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008, 283:13116-13123.
67. Lewerenz J., Albrecht P., Tien M.L., et al. Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J Neurochem 2009, 111:332-343.
68. Yang G.Y., Zhao Y.J., Davidson B.L., Betz A.L. Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 1997, 751:181-188.
69. - activity and astrocytes are necessary for interleukin-1β-mediated hypoxic neuronal injury. J Neurosci 2007, 27:10094-10105.
70. Hara H., Friedlander R.M., Gagliardini V., et al. Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A 1997, 94:2007-2012.
71. Ohtaki H., Takaki A., Yin L., et al. Suppression of oxidative stress after transient focal ischemia in interleukin-1 knock out mice. Acta Neurochir Suppl 2003, 86:191-194.
72. Mulcahy N.J., Ross J., Rothwell N.J., Loddick S.A. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 2003, 140:471-476.
73. Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 2003, 17:152-157.
74. Emsley H.C., Smith C.J., Georgiou R.F., et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005, 76:1366-1372.
75. Matsui T., Mori T., Tateishi N., et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part I: enhanced astrocytic synthesis of S-100β in the periinfarct area precedes delayed infarct expansion. J Cereb Blood Flow Metab 2002, 22:711-722.
76. Hu J., Ferreira A., Van Eldik L.J. S100β induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem 1997, 69:2294-2301.
77. Tateishi N., Mori T., Kagamiishi Y., et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 2002, 22:723-734.
78. Pettigrew L.C., Kasner S.E., Gorman M., Atkinson R.P., Funakoshi Y., Ishibashi H. Effect of arundic acid on serum S-100β in ischemic stroke. J Neurol Sci 2006, 251:57-61. Arundic Acid (ONO-2506) Stroke Study Group.
79. Pettigrew L.C., Kasner S.E., Albers G.W., et al. Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci 2006, 251:50-56. Arundic Acid (ONO-2506) Stroke Study Group.
80. Sorensen A.G., Buonanno F.S., Gonzalez R.G., et al. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. Radiology 1996, 199:391-401.
81. Beaulieu C., de Crespigny A., Tong D.C., Moseley M.E., Albers G.W., Marks M.P. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol 1999, 46:568-578.
82. Olivot J.M., Marks M.P. Magnetic resonance imaging in the evaluation of acute stroke. Top Magn Reson Imaging 2008, 19:225-230.
83. Schwamm L.H., Koroshetz W.J., Sorensen A.G., et al. Time course of lesion development in patients with acute stroke: serial diffusion- and hemodynamic-weighted magnetic resonance imaging. Stroke 1998, 29:2268-2276.
84. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
85. Marti H.H., Gassmann M., Wenger R.H., et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997, 51:416-418.
86. Ruscher K., Freyer D., Karsch M., et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002, 22:10291-10301.
87. Prass K., Scharff A., Ruscher K., et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003, 34:1981-1986.
88. Masuda S., Okano M., Yamagishi K., Nagao M., Ueda M., Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994, 269:19488-19493.
89. Gruber M., Hu C.J., Johnson R.S., Brown E.J., Keith B., Simon M.C. Acute postnatal ablation of Hif-2α results in anemia. Proc Natl Acad Sci U S A 2007, 104:2301-2306.
90. Weidemann A., et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest 2009, 119:3373-3383.
91. Morishita E., Masuda S., Nagao M., Yasuda Y., Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997, 76:105-116.
92. Sakanaka M., Wen T.C., Matsuda S., et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998, 95:4635-4640.
93. Liu J., Narasimhan P., Song Y.S., et al. Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stress. Glia 2006, 53:360-365.
94. Diaz Z., Assaraf M.I., Miller W.H., Schipper H.M. Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. J Neurochem 2005, 93:392-402.
95. Bernaudin M., Marti H.H., Roussel S., et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999, 19:643-651.
96. Sirén A.L., Fratelli M., Brines M., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001, 98:4044-4049.
97. Gonzalez F.F., Abel R., Almli C.R., Mu D., Wendland M., Ferriero D.M. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev Neurosci 2009, 31:403-411.
98. Sola A., Wen T.C., Hamrick S.E., Ferriero D.M. Potential for protection and repair following injury to the developing brain: a role for erythropoietin?. Pediatr Res 2005, 57:110R-117R.
99. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002, 8:495-505.
100. Ehrenreich H., Weissenborn K., Prange H., et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-e656. EPO Stroke Trial Group.
101. Shingo T., Sorokan S.T., Shimazaki T., Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001, 21:9733-9743.
102. Sirén A.L., Fasshauer T., Bartels C., Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009, 6:108-127.
103. Byts N., Sirén A.L. Erythropoietin: a multimodal neuroprotective agent. Exp Transl Stroke Med 2009, 1:4.
104. Siddiq A., Ayoub I.A., Chavez J.C., et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nervous system. J Biol Chem 2005, 280:41732-41743.
105. Rempe D.A., Lelli K.M., Vangeison G., Johnson R.S., Federoff H.J. In cultured astrocytes, p53 and MDM2 do not alter hypoxia-inducible factor-1α function regardless of the presence of DNA damage. J Biol Chem 2007, 282:16187-16201.
106. Lee M.Y., Ju W.K., Cha J.H., et al. Expression of vascular endothelial growth factor mRNA following transient forebrain ischemia in rats. Neurosci Lett 1999, 265:107-110.
107. Sinor A.D., Irvin S.M., Cobbs C.S., Chen J., Graham S.H., Greenberg D.A. Hypoxic induction of vascular endothelial growth factor (VEGF) protein in astroglial cultures. Brain Res 1998, 812:289-291.
108. Beck H., Plate K.H. Angiogenesis after cerebral ischemia. Acta Neuropathol 2009, 117:481-496.
109. Jin K.L., Mao X.O., Greenberg D.A. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 2000, 97:10242-10247.
110. Wick A., Wick W., Waltenberger J., Weller M., Dichgans J., Schulz J.B. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 2002, 22:6401-6407.
111. Bernaudin M., Nedelec A.S., Divoux D., MacKenzie E.T., Petit E., Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 2002, 22:393-403.
112. Plate K.H., Beck H., Danner S., Allegrini P.R., Wiessner C. Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct. J Neuropathol Exp Neurol 1999, 58:654-666.
113. Jian Liu K., Rosenberg G.A. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 2005, 39:71-80.
114. Cunningham L.A., Wetzel M., Rosenberg G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005, 50:329-339.
115. Asahi M., Asahi K., Jung J.C., del Zoppo G.J., Fini M.E., Lo E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000, 20:1681-1689.
116. Wardas J. Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 2002, 54:313-326.
117. + channels in cerebral ischemic preconditioning. Proc Natl Acad Sci U S A 1995, 92:4666-4670.
118. Lin J.H., Lou N., Kang N., et al. A central role of connexin 43 in hypoxic preconditioning. J Neurosci 2008, 28:681-695.
119. Williams-Karnesky R.L., Stenzel-Poore M.P. Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant. Curr Neuropharmacol 2009, 7:217-227.
120. Kang J., Kang N., Lovatt D., et al. Connexin 43 hemichannels are permeable to ATP. J Neurosci 2008, 28:4702-4711.
121. Robson S.C., Sévigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2006, 2:409-430.
122. Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci 2006, 27:652-658.
123. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 2005, 11:25-36.
124. Grenz A., Zhang H., Hermes M., et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007, 21:2863-2873.
125. Köhler D., Eckle T., Faigle M., et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 2007, 116:1784-1794. [Erratum in: Circulation 2007;116:e514.].
126. Kochanek P.M., Vagni V.A., Janesko K.L., et al. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 2006, 26:565-575.
127. Pignataro G., Simon R.P., Boison D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J Cereb Blood Flow Metab 2007, 27:1-5.
128. Olsson T., Cronberg T., Rytter A., et al. Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro. Eur J Neurosci 2004, 20:1197-1204.
129. von Lubitz D.K. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?. Eur J Pharmacol 1999, 371:85-102.
130. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999, 19:9192-9200.
131. O'Regan M.H., Simpson R.E., Perkins L.M., Phillis J.W. The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci Lett 1992, 138:169-172.
132. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 1995, 287:215-217.
133. Stone T.W., Ceruti S., Abbracchio M.P. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009, (193):535-587.
134. Farahani R., Pina-Benabou M.H., Kyrozis A., et al. Alterations in metabolism and gap junction expression may determine the role of astrocytes as "good samaritans" or executioners. Glia 2005, 50:351-361.
135. Juszczak G.R., Swiergiel A.H. Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:181-198.
136. de Pina-Benabou M.H., Szostak V., Kyrozis A., et al. Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. Stroke 2005, 36:2232-2237.
137. Vakili A., Hosseinzadeh S.A., Khorasani M.Z. Peripheral administration of carbenoxolone reduces ischemic reperfusion injury in transient model of cerebral ischemia. J Stroke Cerebrovasc Dis 2009, 18:81-85.
138. Perez Velazquez J.L., Kokarovtseva L., Sarbaziha R., Jeyapalan Z., Leshchenko Y. Role of gap junctional coupling in astrocytic networks in the determination of global ischaemia-induced oxidative stress and hippocampal damage. Eur J Neurosci 2006, 23:1-10.
139. Turpie A.G., Thomson T.J. Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects. Gut 1965, 6:591-594.
140. Nakase T., Söhl G., Theis M., Willecke K., Naus C.C. Increased apoptosis and inflammation after focal brain ischemia in mice lacking connexin43 in astrocytes. Am J Pathol 2004, 164:2067-2075.
141. Nudo R.J. Postinfarct cortical plasticity and behavioral recovery. Stroke 2007, 38:840-845.
142. Carmichael S.T. Plasticity of cortical projections after stroke. Neuroscientist 2003, 9:64-75.
143. Hamilton N.B., Attwell D. Do astrocytes really exocytose neurotransmitters?. Nat Rev Neurosci 2010, 11:227-238.
144. Barker A.J., Ullian E.M. Astrocytes and synaptic plasticity. Neuroscientist 2010, 16:40-50.
145. Liauw J., Hoang S., Choi M., et al. Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke. J Cereb Blood Flow Metab 2008, 28:1722-1732.
146. Christopherson K.S., Ullian E.M., Stokes C.C., et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 2005, 120:421-433.
147. Kyriakides T.R., MacLauchlan S. The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal 2009, 3:215-225.
148. Eroglu C., Allen N.J., Susman M.W., et al. Gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009, 139:380-392.
149. Li Y., Chopp M. Marrow stromal cell transplantation in stroke and traumatic brain injury. Neurosci Lett 2009, 456:120-123.
150. Chopp M., Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002, 1:92-100.
151. Liu Z., Li Y., Zhang Z.G., et al. Bone marrow stromal cells enhance inter- and intracortical axonal connections after ischemic stroke in adult rats. J Cereb Blood Flow Metab 2010, 30:1288-1295.
152. Gao Q., Li Y., Chopp M. Bone marrow stromal cells increase astrocyte survival via upregulation of phosphoinositide 3-kinase/threonine protein kinase and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways and stimulate astrocyte trophic factor gene expression after anaerobic insult. Neuroscience 2005, 136:123-134.
153. Xin H., Li Y., Shen L.H., et al. Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse. PLoS ONE 2010, 5:e9027.